A review of phase II and III drugs for the treatment and management of endometriosis

IF 2.7 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Opinion on Emerging Drugs Pub Date : 2023-12-15 DOI:10.1080/14728214.2023.2296080

Umberto Perrone, Giulio Evangelisti, Antonio Simone Laganà, Stefano Bogliolo, Marcello Ceccaroni, Alberto Izzotti, Claudio Gustavino, Simone Ferrero, Fabio Barra

引用次数: 0

Abstract

Endometriosis is an estrogen-dependent disease that gives rise to pelvic pain and infertility. Although estroprogestins and progestins currently stand as the first-line treatments for this conditio...

查看原文本刊更多论文

治疗和管理子宫内膜异位症的二期和三期药物综述

子宫内膜异位症是一种雌激素依赖性疾病，会导致盆腔疼痛和不孕。虽然雌激素和孕激素目前是治疗这种疾病的一线药物，但它们对子宫内膜异位症的治疗效果并不理想。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Emerging Drugs 医学-药学

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.